Key Scientific Presentations and Publications

We measure ourselves by the impact we have on people with devastating diseases.
Let’s wage science.

SpringWorks is committed to advancing science and helping unlock the full potential of targeted oncology. We strive to publish papers in peer-reviewed journals and share scientific presentations of our work at medical congresses so others can build on it. You can find them here.
Desmoid tumor conference presentations

Desmoid tumor publications

Ovarian granulosa cell tumor conference presentations

Ovarian granulosa cell tumor publications

  • Li J, Bao R, Peng S, Zhang C. The molecular mechanism of ovarian granulosa cell tumors. J Ovarian Res. 2018;11(1):13.
  • Irusta G, Pazos MC, Abramovich D, De Zúñiga I, Parborell F, Tesone M. Effects of an inhibitor of the γ-secretase complex on proliferation and apoptotic parameters in a FOXL2-mutated granulosa tumor cell line (KGN). Biol Reprod. 2013;89(1):9.
  • Shah SP, Kobel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360(26):2719-2729.

Multiple myeloma conference presentations

Multiple myeloma publications

  • Cowan AJ, Pont MJ, Sather BD, et al. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023;24(7):811-822.
  • Rodriguez C, Weisel K, Baz RC, et al. Dose escalation and expansion of Abbv-383 in combination with anti-cancer regimens in relapsed or refractory multiple myeloma. Blood. 2022;140(Supplement 1):7326-7327.
  • Pillarisetti K, Powers G, Luistro L, et al. Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Advances. 2020:4(18):4538-4549.
  • Pont MJ, Hill T, Cole GO, et al. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585-1597.

NF1 conference presentations

NF1 publications

  • Weiss BD, Wolters PL, Plotkin SR, et al. NF106: a Neurofibromatosis Clinical Trials Consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. J Clin Oncol. 2021;39(7):797-806.*
  • Jousma E, Rizvi TA, Wu J, et al. Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1. Pediatr Blood Cancer. 2015;62(10):1709-1716.*
  • Jessen WJ, Miller SJ, Jousma E, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013;123(1):340-347.*
Other mirdametinib conference presentations

Other mirdametinib publications

  • Vinitsky A, Chiang J, Bag AK, et al. Phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG). Neuro Oncol. 2022;24(Supplement_1):i92.
  • Yuan X, Tang Z, Du R, et al. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors. Mol Oncol. 2020;14(8):1833-1849.
  • LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res. 2010;16(6):1924-1937.

Brimarafenib conference presentations

Brimarafenib publications

  • Wang J, Yao Z, Jonsson P, et al. A secondary mutation in BRAF confers resistance to RAF inhibition in a BRAFV600E-mutant brain tumor. Cancer Discovery. 2018;8(9):1130-1141.
  • Dankner M, Rose AAN, Rajkumar S, et al. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37(24):3183-3199.
  • Yao Z, Torres NW, Tao A, et al. BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell. 2015;28(3):370-383.

Preclinical program conference presentations

Preclinical publications

* Indicates that the publication is based on investigator-initiated research

** Indicates that the publication is based on a compassionate use program

On this page you may select links to key publications from peer-reviewed journals as well as to materials presented at scientific conferences relating to either research studies involving SpringWorks’ product candidates or to the science guiding our discovery, research, and development efforts. The safety and efficacy of any investigational product discussed in these materials has yet to be determined. Note that certain of these materials were authored by unaffiliated third parties and do not represent SpringWorks’ views. The content of each work is the property of the respective copyright holder and may not be further distributed without their express permission. The information in these materials may not be current or comprehensive, and SpringWorks undertakes no obligation to correct or update such information.